RT Journal Article
SR Electronic
T1 Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.02.18.25322379
DO 10.1101/2025.02.18.25322379
A1 Bhattacharjee, Bornali
A1 Lu, Peiwen
A1 Monteiro, Valter Silva
A1 Tabachnikova, Alexandra
A1 Wang, Kexin
A1 Hooper, William B.
A1 Bastos, Victoria
A1 Greene, Kerrie
A1 Sawano, Mitsuaki
A1 Guirgis, Christian
A1 Tzeng, Tiffany J.
A1 Warner, Frederick
A1 Baevova, Pavlina
A1 Kamath, Kathy
A1 Reifert, Jack
A1 Hertz, Danice
A1 Dressen, Brianne
A1 Tabacof, Laura
A1 Wood, Jamie
A1 Cooke, Lily
A1 Doerstling, Mackenzie
A1 Nolasco, Shadan
A1 Ahmed, Amer
A1 Proal, Amy
A1 Putrino, David
A1 Guan, Leying
A1 Krumholz, Harlan M.
A1 Iwasaki, Akiko
YR 2025
UL http://medrxiv.org/content/early/2025/02/25/2025.02.18.25322379.abstract
AB COVID-19 vaccines have prevented millions of COVID-19 deaths. Yet, a small fraction of the population reports a chronic debilitating condition after COVID-19 vaccination, often referred to as post- vaccination syndrome (PVS). To explore potential pathobiological features associated with PVS, we conducted a decentralized, cross-sectional study involving 42 PVS participants and 22 healthy controls enrolled in the Yale LISTEN study. Compared with controls, PVS participants exhibited differences in immune profiles, including reduced circulating memory and effector CD4 T cells (type 1 and type 2) and an increase in TNFα+ CD8 T cells. PVS participants also had lower anti-spike antibody titers, primarily due to fewer vaccine doses. Serological evidence of recent Epstein-Barr virus (EBV) reactivation was observed more frequently in PVS participants. Further, individuals with PVS exhibited elevated levels of circulating spike protein compared to healthy controls. These findings reveal potential immune differences in individuals with PVS that merit further investigation to better understand this condition and inform future research into diagnostic and therapeutic approaches.Competing Interest StatementIn the past three years, H.M.K. received expenses and/or personal fees from United Health, Element Science, Eyedentifeye and F-Prime; he is a co-founder of Refactor Health, HugoHealth and MedRxiv; and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services and through Yale University from the Food and Drug Administration, Johnson & Johnson, Google and Pfizer. A.I. co-founded and consults for RIGImmune, Xanadu Bio and PanV and is a member of the Board of Directors of Roche Holding and Genentech. B.D. reports being a plaintiff in a lawsuit against AstraZeneca alleging breach of contract following her volunteer participation in 2020 in their COVID-19 vaccine clinical trial. She is also a co-chair of REACT19, a non-profit organization offering financial, physical, and emotional support for those suffering from long term COVID-19 vaccine adverse events. D.H serves on the Advisory Board of REACT19.Funding StatementThis study was funded in part by the Howard Hughes Medical Institute Collaborative COVID-19 Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Yale University Institutional Review Board on April 1, 2022 (HIC# 2000032207). Informed consent was provided by participants electronically. Each participant was assigned a unique identifier as part of the de-identification protocol managed by the study coordinator. These identifiers were kept confidential and were not accessible to anyone outside the research team. A subset of the MY-LC cohort approved by the Mount Sinai Program for the Protection of Human Subjects (#20-01758) were included for validation of one of the assays.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe flow data repository ID is FR-FCM-Z8FZ for all the raw .fcs files generated for flow cytometry analyses at the Flow Repository platform. Custom codes used for computational analyses will be made available by authors upon reasonable request.